The effect of a nitro-aspirine on apoptosis of neutrophil granulocytes

Acta Veterinaria

Volumn 57, Issue 5-6, 2007, Pages 403-412

  Vasilev, S ^a   Vučević, Dragana ^a   Gašić, Sonja ^a   Majstorović, Ivana ^a   Vasilijic S ^a   Colic M ^a   Ćupić, Vitomir ^b  

^a UNIVERSITY OF DEFENCE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Apoptosis; Neutrophil granulocytes; Nitro aspirin

Indexed keywords

RATTUS;

EID: 38549179218     PISSN: 05678315     EISSN: None     Source Type: Journal    
DOI: 10.2298/AVB0706403V     Document Type: Article

References (42)

1. Akgul C, Moulding DA, Edwards SWI, 2001, Molecular control of neutrophil apoptosis, FEBS letters, 487, 318-22.
2. Awtry EH, Loscalzo J, 2000, Aspirin. Circulation, 101, 1206-18.
3. Bandarage UK, Janero DR, 2001, Nitric oxide-releasing nonsteroidal anti-inflammatory drugs: novel gastrointestinal-sparing drugs, Mini Rev Med Chem, 1, 1, 57-70.
4. Blaise GA, Gauvin D, Gangal M, Authier S, 2005, Nitric oxide, cell signaling and cell death, Toxicol, 208, 2, 177-92.
5. Bogdan C, Röllinghoff M, Diefenbach A, 2000, Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity, Curr Opp Immunol, 12, 64-76.
6. Bolla M, Momi S, Gresele P, Del Soldato P, 2006, Nitric oxide-donating aspirin (NCX 4016): an overview of its pharmacological properties and clinical perspectives, Eur J Clin Pharmacol, 62, Suppl 1, 145-54.
7. Brune B, von Knethen A, Sandau KB, 1999, Nitric oxide (NO): an effector of apoptosis, Cell death and differentiation, 6, 969-75.
8. Burgaud JL, Riffaud JP, Del Soldato P, 2002, Nitric-oxide releasing molecules: a new class of drugs with several major indications, Curr Pharm Des, 8, 3, 201-13.
9. Čolic M, 2004, Apoptoza neutrofilnih granulocita i njen značaj za regulaciju inflamacije. U: Apoptoza - eksperimentalna i klinička iskustva. Zbornik radova sa naučnog skupa. Urednik: ZL Kovačević. Srpska akademija nauka i umetnosti, Ogranak Novi Sad, 69-80.
10. Ćupić V, 1999, Najčešća trovanja u veterinarskoj medicini, IŠ Stručna knjiga, Beograd,
11. del Soldato P, Sorrentino R, Pinto A, 1999, NO-aspirins: a class of new anti-inflammatory and antithrombotic agents, Trends Pharmacol Sci, 20, 8, 319-23.
12. Di Napoli M, Papa F, 2003, NCX-4016 NicOx, Curr Opin Investig Drugs, 4, 9, 1126-39.
13. Dlamini Z, Mbita Z, Zungu M, 2004, Genealogy, expresion, and molecular mechanisms in apoptosis, Pharmacol Therap, 101, 1-15
14. Elliot SN, McKnight W, Cirino G, Wallace JL, 1995, A nitric oxide-releasing NSAID accelerates gastric ulcer healing in rats, Gastroenterol, 109, 2, 524-30.
15. Fiorucci S, Distrutti E, Mencarelli A, Rizzo G, Lorenzo AR, Baldoni M et al, 2004, Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(acetyloxy)benzoic acid 3-(nitrooxymethyl) phenyl ester (NCX-4016) (NO-aspirin) on neutrophil- endothelial cell adherence, J Pharmacol Exp Ther, 309, 1174-82.
16. Fiorucci S, Mencarelli A, Meneguzzi A, Lechi A, Morelli A, Del Soldato P, Minuz P, 2002, NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide, Circulation, 106, 3120-25.
17. Fiorucci S, Santucci L, Cirino G, Mencarelli A, Familiari L, Del Soldato P et al, 2000, IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs, J Immunol, 165, 5245-54.
18. Fiorucci S, Santucci L, Wallace JL, Sardina M, Romano M, del Soldato P et al, 2003, Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa, Proc Nat Acad Sci USA, 100, 10937-41.
19. Girard D, 2003, Activation of human polymorphonuclear neutrophils by environmental contaminants, Rev Environ Health, 18, 2, 77-93.
20. 15N) nitrate in biological fluids, Anal biochem, 126, 131-8.
21. Grosser N, Schröder H, 2000, A common pathway for nitric oxide release from NO-aspirin and glyceryl trinitrate, Biochem Biophys Res Comm, 274, 255-8.
22. Guimaraes CA, and Linden R, 2004, Programed cell death, Eur J Biochem, 271, 1638-50.
23. Hinz B, Brune K, 2002, Cyclooxigenase-2 - 10 years later, J Pharmacol Exp Therap, 300, 367-75.
24. Hunter R, 2002, Nitric oxide, iNOS and inflammation in veterinary medicine, Anim Health Res Rev, 3, 2, 119-33.
25. Kam PCA, Ferch NI, 2000, Apoptosis: mechanisms and clinical implications, Anaesthesia, 55, 1081-93.
26. Kashfi K, Ryan Y, Qiao LL, Williams JL, Chen J, Del Soldato P et al, 2003, Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect, J Pharmacol Exp Ther, 303, 3, 1273-82.
27. Maianski NA, Maianski AN, Kuijpers TW, Roos D, 2004, Apoptosis of neutrophils, Acta Haematol, 111, 56-66.
28. Mariotto S, Menegazzi M, Carcereri de Prati A, Cuzzolin L, Adami A, Suzuki HG et al, 1995, Protective effect of NO on gastric lesions and inhibition of expression of gastric iNOS by flurbiprofen and its nitro derivative, nitroflurbiprofen, Br J Pharmacol, 116, 1713-4.
29. Migita K, Eguchi K, Kawabe Y, Mizokami A, Tsukada T, Nagataki S, 1994, Prevention of anti-CD3 monoclonal antibody-induced thymic apoptosis by protein tyrosine kinase inhibitors, J Immunol, 153, 8, 3457-65.
30. Moncada S, Palmer RMJ, Higgs EA, 1991, Nitric oxide: physiology, patophysiology and pharmacology, Pharmacol Rev, 43, 2, 109-41.
31. Muscara MN, McKnight W, Del Soldato P, Wallace JL, 1998, Effect of NO-naproksen on hxpertension amnd gastric damage induced by chronic NO inhibition in the rat, Life Sci, 62, PL 235-PL 240.
32. Napoli C, Ignarro LJ, 2003, Nitric oxide - releasing drugs, Ann Rev Pharmacol Toxicol, 43, 97-123.
33. Simon HU, 2003, Neutrophil apoptosis pathway and their modifications in inflammation, Immunol Rev, 193, 101-10
34. Taylor EL, Megson IL, Haslett C, Rossi AG, 2003, Nitric oxide: a key regulator of myeloid inflammatory cell Apoptosis, Cell Death Differ, 10, 418-30.
35. Tesei A, Ricotti L, Ulivi P, Medri L, Amadori D, Zoli W, 2003, NCX-4016, a nitric oxide-releasing aspirin derivative, exhibits a significant antiproliferative effect and alters cell cycle progression in human colon adenocarcinoma cell lines, Int J Oncology, 22, 1297-302.
36. Vane JR, Bakhle YS, Botting RM, 1998, Cyclooxigenases 1 and 2, Ann Rev Pharmacol Toxicol, 38, 97-120.
37. Jezdimirović Milanka, Varagić MV, Ćupić V, Jeftić Zorica, 1996, Nesteroidni antiinflamatorni lekovi u veterinarskoj medicini, Veterinarski glasnik, 50, 9-10, 679-87.
38. Vasilev S, Majstorović Ivana, Gašić Sonja, Vučević Dragana, Vasilijić S, Ćupić V et al, 2006, The effects of aspirin on apoptosis of neutrophil granulocytes, Acta Veterinaria, 56, 5-6, 413-21.
39. Wallace JL, Zamuner SR, McKnight W, Dicay M, Mencarelli A, del Soldato P et al, 2004, Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation, Am J Physiol Gastrointest Liver Physiol, 286, 1, G76-81.
40. Ward C, Dransfield I, Chilvers ER, Haslett C, Rossi AG, 1999, Pharmacological manipulation of granulocyte apoptosis: potential therapeutic targets, TIPS, 20, 503-9.
41. Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L et al, 2003, Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cycloxygenase-2 induction and beta-catenin/T-cell factor signalling, nuclear factor-kB, and NO-syntase 2 inhibitioon: implication for chemoprevention, Canc Res, 63, 7613-18.
42. Witko-Sarsat V, Rieu P, Descamps-Latscha B, Lesavre P, Halbwachs-Mecarelli L, 2000, Neutrophils: molecules, functions and pathophysiological aspects, Lab Invest, 80, 5, 617.